Navigation Links
Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
Date:10/12/2009

ST. LOUIS, Oct. 12 /PRNewswire/ -- Orion Genomics today announced that it has entered into a multi-year collaboration and license agreement with the molecular diagnostics unit of Novartis Pharma AG. Under the collaboration, the parties seek to discover novel epigenetic biomarkers, and both parties have rights to independently develop and commercialize diagnostic products in their respective fields. Under the terms of the agreement, Orion Genomics also grants Novartis non-exclusive world-wide rights to its proprietary MethylScreen clinical assay technology. Financial terms were not disclosed.

"Epigenetic changes can play a key role in certain disease biology, and could lead to the development of important new diagnostic tools," said Nathan D. Lakey, President and CEO of Orion Genomics. "Ultimately, our collaboration with Novartis Molecular Diagnostics aims to support the development of innovative tests which we hope will provide physicians and patients with better information to guide treatment decisions."

The collaboration will leverage Orion Genomics' MethylScope® Technology to build high-resolution genome-wide DNA methylation maps for the discovery of epigenetic biomarkers in multiple disease fields. Novartis also obtains a non-exclusive license to MethylScreen® Technology, Orion's PCR-based clinical assay platform that quantitatively detects epigenetic biomarkers in patient samples. Under the agreement, Orion and Novartis intend to develop and commercialize promising diagnostic products that address various stages of disease. Resulting diagnostic tests could lead to advances in personalized medicine, potentially helping doctors optimize the treatment of patients.

"Science is revealing that epigenetics is a potent driver of disease biology and therapeutic response and a potential linchpin in the efforts to make personalized medicine a reality," said Howard McLeod, Professor of Medicine and Pharmacy and Director of the University of North Carolina Institute for Individualized Therapy. "As we consider how to optimize the use of the healthcare dollar, leveraging personalized medicine tools such as epigenetics to do a better job of matching individual patients with effective therapies will become ever more important."

Orion Genomics' MethylScope and MethylScreen technologies are used to discover and validate epigenetic biomarkers, which are changes to a layer of information written on top of the DNA molecule in the form of DNA methylation. DNA methylation controls whether or not a gene is turned on or off, also called gene-silencing. Epigenetic changes can be associated with disease risk, disease progression, and response to therapy.

About Orion Genomics

Orion Genomics, the Second Code Company, develops epigenetic research tools and molecular diagnostic products to fulfill the promise of personalized medicine. Orion's lead product is a simple blood-based test being developed to identify people at elevated risk for colorectal cancer. The company has active biomarker discovery programs in cancers of the bladder, breast, lung, ovaries and colon, and the company offers genomics services to the medical and agricultural and bio-fuels research communities. Orion Genomics is located in the Center for Emerging Technologies in St. Louis. For more information, visit the Orion Genomics website at http://www.oriongenomics.com.

SOURCE Orion Genomics


'/>"/>
SOURCE Orion Genomics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
2. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
3. Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
4. Curemark CEO Presents at Epigenomics Conference
5. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
6. Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
7. First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology
8. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
9. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
10. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
11. Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... Driving Dynamics Inc., announced today it has been selected as ... part of its mission to continually monitor the training marketplace for the best providers ... 20 Health and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard ... businesses and organizations become more efficient and improve customer satisfaction. ISO 9001:2015 was released ... own QMS, with a deadline of September 2018. , As described in ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone ... launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is ... the U.S. to incorporate magnesium, a critical property for bone health and development. ...
(Date:9/19/2017)... ... , ... First Choice Emergency Room , the largest network of independent ... Medical Director of its Pflugerville- FM 685 facility. , “We are pleased to ... 685 location,” said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... the country with the Davidson Fellows Scholarship on September 27 at a reception ... in Science, Technology, Engineering, Mathematics, Literature and Music. , “I am honored to ...
Breaking Medicine News(10 mins):